X

Trial Profile

Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golimumab (Primary)
Indications Axial spondyloarthritis
Focus Therapeutic Use
Acronyms MANGO

Most Recent Events

04 Jun 2022 Results examining the construct validity and responsiveness of ASAS HI (Assessment of Spondyloarthritis International Society Health Index ) in relation to TNFi treatment, presented at the 23rd Annual Congress of the European League Against Rheumatism
20 Apr 2020 Results published in the Rheumatology
04 Jan 2019 Status changed from not yet recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com